A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer

Andrew Artz, Walter M. Stadler, Nicholas J. Vogelzang, Todd Zimmerman, Christopher Ryan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Administration of noncross-resistant agents in a sequential fashion may improve outcome by targeting tumor cells with different sensitivity profiles. We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with metastatic or unresectable transitional cell carcinoma of the urothelium. Patients received 3 cycles of DM (40 mg/m2 methotrexate on days 1 and 8 and 100 mg/m 2 docetaxel on day 8 repeated every 21 days) followed by GC (1000 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 cisplatin on day 1 repeated every 21 days). The most common toxicities were hematologic, with grade 3/4 neutropenia and thrombocytopenia observed in 4 and 2 patients, respectively. Four partial responses were observed after DM (4 of 12, 33% response rate) and 6 responses (3 partial response, 3 complete response, 6 of 9, 67% response rate) after GC for an overall response rate of 7 of 13 (54%). Three patients who progressed on DM responded to GC and 3 responders to DM achieved further response to GC. The median overall survival was 13.6 months. Although we do not recommend this particular sequence of chemotherapy for further study, the uncompromised median survival and the ability to salvage responses with GC suggest that testing of novel agents in sequence with GC is a feasible strategy.

Original languageEnglish (US)
Pages (from-to)109-113
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

docetaxel
gemcitabine
Methotrexate
Cisplatin
Drug Therapy
Neoplasms
Urothelium
Survival
Transitional Cell Carcinoma
Neutropenia

Keywords

  • Antineoplastic combined chemotherapy protocols
  • Carcinoma
  • Drug evaluation
  • Transitional cell

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. / Artz, Andrew; Stadler, Walter M.; Vogelzang, Nicholas J.; Zimmerman, Todd; Ryan, Christopher.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 28, No. 2, 04.2005, p. 109-113.

Research output: Contribution to journalArticle

@article{d462d3ea49e74f7b8d0b34cbeec03204,
title = "A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer",
abstract = "Administration of noncross-resistant agents in a sequential fashion may improve outcome by targeting tumor cells with different sensitivity profiles. We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with metastatic or unresectable transitional cell carcinoma of the urothelium. Patients received 3 cycles of DM (40 mg/m2 methotrexate on days 1 and 8 and 100 mg/m 2 docetaxel on day 8 repeated every 21 days) followed by GC (1000 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 cisplatin on day 1 repeated every 21 days). The most common toxicities were hematologic, with grade 3/4 neutropenia and thrombocytopenia observed in 4 and 2 patients, respectively. Four partial responses were observed after DM (4 of 12, 33{\%} response rate) and 6 responses (3 partial response, 3 complete response, 6 of 9, 67{\%} response rate) after GC for an overall response rate of 7 of 13 (54{\%}). Three patients who progressed on DM responded to GC and 3 responders to DM achieved further response to GC. The median overall survival was 13.6 months. Although we do not recommend this particular sequence of chemotherapy for further study, the uncompromised median survival and the ability to salvage responses with GC suggest that testing of novel agents in sequence with GC is a feasible strategy.",
keywords = "Antineoplastic combined chemotherapy protocols, Carcinoma, Drug evaluation, Transitional cell",
author = "Andrew Artz and Stadler, {Walter M.} and Vogelzang, {Nicholas J.} and Todd Zimmerman and Christopher Ryan",
year = "2005",
month = "4",
doi = "10.1097/01.coc.0000142591.62299.8f",
language = "English (US)",
volume = "28",
pages = "109--113",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer

AU - Artz, Andrew

AU - Stadler, Walter M.

AU - Vogelzang, Nicholas J.

AU - Zimmerman, Todd

AU - Ryan, Christopher

PY - 2005/4

Y1 - 2005/4

N2 - Administration of noncross-resistant agents in a sequential fashion may improve outcome by targeting tumor cells with different sensitivity profiles. We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with metastatic or unresectable transitional cell carcinoma of the urothelium. Patients received 3 cycles of DM (40 mg/m2 methotrexate on days 1 and 8 and 100 mg/m 2 docetaxel on day 8 repeated every 21 days) followed by GC (1000 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 cisplatin on day 1 repeated every 21 days). The most common toxicities were hematologic, with grade 3/4 neutropenia and thrombocytopenia observed in 4 and 2 patients, respectively. Four partial responses were observed after DM (4 of 12, 33% response rate) and 6 responses (3 partial response, 3 complete response, 6 of 9, 67% response rate) after GC for an overall response rate of 7 of 13 (54%). Three patients who progressed on DM responded to GC and 3 responders to DM achieved further response to GC. The median overall survival was 13.6 months. Although we do not recommend this particular sequence of chemotherapy for further study, the uncompromised median survival and the ability to salvage responses with GC suggest that testing of novel agents in sequence with GC is a feasible strategy.

AB - Administration of noncross-resistant agents in a sequential fashion may improve outcome by targeting tumor cells with different sensitivity profiles. We evaluated the toxicity and response rate of docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) in patients with metastatic or unresectable transitional cell carcinoma of the urothelium. Patients received 3 cycles of DM (40 mg/m2 methotrexate on days 1 and 8 and 100 mg/m 2 docetaxel on day 8 repeated every 21 days) followed by GC (1000 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 cisplatin on day 1 repeated every 21 days). The most common toxicities were hematologic, with grade 3/4 neutropenia and thrombocytopenia observed in 4 and 2 patients, respectively. Four partial responses were observed after DM (4 of 12, 33% response rate) and 6 responses (3 partial response, 3 complete response, 6 of 9, 67% response rate) after GC for an overall response rate of 7 of 13 (54%). Three patients who progressed on DM responded to GC and 3 responders to DM achieved further response to GC. The median overall survival was 13.6 months. Although we do not recommend this particular sequence of chemotherapy for further study, the uncompromised median survival and the ability to salvage responses with GC suggest that testing of novel agents in sequence with GC is a feasible strategy.

KW - Antineoplastic combined chemotherapy protocols

KW - Carcinoma

KW - Drug evaluation

KW - Transitional cell

UR - http://www.scopus.com/inward/record.url?scp=17044404567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044404567&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000142591.62299.8f

DO - 10.1097/01.coc.0000142591.62299.8f

M3 - Article

C2 - 15803001

AN - SCOPUS:17044404567

VL - 28

SP - 109

EP - 113

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -